Human CD155 / PVR Protein
- Known as:
- Human CD155 / PVR Protein
- Catalog number:
- CD5-H5223
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human CD155 / PVR Protein
Related genes to: Human CD155 / PVR Protein
- Gene:
- PVR NIH gene
- Name:
- PVR cell adhesion molecule
- Previous symbol:
- PVS
- Synonyms:
- CD155, HVED, Necl-5, NECL5, Tage4
- Chromosome:
- 19q13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-03-14
Related products to: Human CD155 / PVR Protein
Related articles to: Human CD155 / PVR Protein
- Glioma is an aggressive brain malignancy characterized by a markedly immunosuppressive microenvironment and limited response to conventional treatments. CD155, also known as the poliovirus receptor, is frequently overexpressed in glioma and plays a key role in immune escape. By interacting with inhibitory receptors such as TIGIT and CD96, as well as the activating receptor CD226, CD155 modulates the tumor immune landscape. These interactions suppress the cytotoxic activity of T cells and natural killer (NK) cells while promoting immunoregulatory phenotypes, thereby impairing immune-mediated tumor cell elimination and supporting tumor progression. The balance among these receptor-ligand interactions is critical in determining immune outcomes. Targeting the CD155 axis has emerged as a potential therapeutic strategy. Approaches including monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor (CAR)-engineered immune cells are being developed to counteract immune suppression and restore antitumor responses. This review summarizes the structural and functional features of CD155 and its associated receptors, examines their roles in glioma immune evasion, and discusses recent advances and challenges in developing therapies targeting this pathway. Modulation of CD155-related signaling may offer new opportunities to improve treatment outcomes in glioma. - Source: PubMed
Publication date: 2026/05/22
Huang MingyaoCui YouchenWang XiaoqianWeng YangHuang HuiyanSu WeiweiZhao ShanLi Yan - Extracorporeal membrane oxygenation (ECMO) traditionally delivers continuous flow, which may be associated with increased pulmonary edema and biotrauma. We hypothesized that electrocardiogram (ECG)-synchronized pulsatile flow may help mitigate these effects. - Source: PubMed
Publication date: 2026/05/22
Day Jonathan WHagiwara JunyaSousse Linda EEnkhbaatar PerenleiDellaVolpe Jeffrey D - Pulmonary arterial hypertension (PAH) is a rare, progressive pulmonary vascular disorder characterized by pulmonary arteriole remodeling leading to increased pulmonary vascular resistance (PVR). PAH is characterized by vascular pruning and plexiform lesion formation. While these features have been described histologically, a detailed quantitative analysis is lacking. In this study, we used micro-computed tomography (µCT) to provide three-dimensional quantification of pulmonary vascular alterations. - Source: PubMed
Publication date: 2026/05/21
Aerts GitteWillems LynnTielemans BirgerMuscogiuri EmanueleVermaut AstridHardy LauraKerckhof PieterjanGeudens VincentMohamady YousryJin XinHooft CharlotteZapata-Ortega MartaBeeckmans HanneVan Slambrouck JanMichiels JolineCelen RubenDe Jonghe BaptisteBoon MiekeBouneb SofianDupont Lieven JBos SaskiaDe Sadeleer Laurens JEveraerts StephanieVos RobinCeulemans Laurens JVan Raemdonck DirkVerbelen TomPerros FrédéricDelcroix MarionQuarck RozennVanaudenaerde Bart MGodinas Laurent - Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension (PH) resulting from unresolved, organized thromboemboli within the pulmonary arterial tree, most often following an acute pulmonary embolic event. A distinctive feature of CTEPH is the development of secondary microvascular or small vessel disease (SVD), which has been associated with adverse surgical outcomes and persistent PH after pulmonary endarterectomy (PEA). While macrovascular disease can be reliably assessed with current imaging techniques, preoperative evaluation of SVD remains a significant diagnostic challenge. This focused review aims to summarize current imaging approaches to SVD in CTEPH, discuss their limitations, and highlight emerging techniques and future directions for improved assessment. - Source: PubMed
Publication date: 2026/04/20
Soares Luciana EltzAlkaabneh ZaidRenapurkar Rahul D - Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, is a high-efficacy therapy for multiple sclerosis (MS). - Source: PubMed
Publication date: 2026/05/20
Roos IzanneSharmin SifatHorakova DanaKubala Havrdova EvaLibertinova JanaVachova MartaAlroughani RaedBoz CavitRous ZuzanaBuzzard KatherineSkibina OlgaPeterka MarekHradilek PavelMares MiroslavColes AlasdairBrown J William LEichau Madueño SaraFoschi MatteoPrevost JulieTerzi MuratPrat AlexandreGirard MarcMeca-Lallana Jose EJohn NevinBlanco Yolandavan der Walt AnnekeButzkueven HelmutRecmanova EvaLaureys GuyAmpapa RadekMacdonell RichardPavelek ZbysekKhoury Samia JosephD'Amico EmanueleGerlach OliverVan Pesch VincentMaimone DavideRomero-Ferrando BeatrizMcCombe Pamela AMrabet SalouaWillekens BarbaraCárdenas-Robledo SimónRamo-Tello CristinaStourac PavelHouskova JanaShaygannejad VahidHodgkinson SuzanneCartechini ElisabettaKermode Allan GFabis-Pedrini MarzenaCarroll William MSlee MarkSánchez-Menoyo José LuisAl-Asmi AbdullahMathey GuillaumeGiannesini ClaireMichel LaureCiron JonathanDe Sèze JérômeRuet AurelieKwiatkowski ArnaudZephir HelenePapeix CarolineLebrun-Frenay ChristineMoreau ThibaultBerger EricClavelou PierrePelletier JeanCasez OlivierBourre BertrandWahab AbirMagy LaurentCamdessanché Jean-PhilippeDoghri InesTchikviladze MaiaSellebjerg FinnRomme Christensen JeppeJensen Henrik BoyeIlles ZsoltBramow StephanRasmussen Peter VStilund Morten LeifSchäfer JakobKant MatthiasWeglewski ArkadiuszVukusic SandraMagyari MelindaLaplaud David-AxelKalincik Tomas